Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiolabeled RE104 ADME study in healthy volunteers
NCT07146191Phase 1Completed
- Sponsor
- Reunion Neuroscience
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RE104, sponsored by Reunion Neuroscience. Primary endpoints: Total Excreted Radioactivity at 168 hours, Cumulative Recovery of Total Excreted Radioactivity at 168 hours and 9 more. Started Aug 2025; status: completed.
02
Drugs
RE104
Beyond the preview
Go deeper on NCT07146191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146191.